Cited by 627Dermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisT-cell and B-cell Immunology

IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells

Open access
Nograles, Kristine E., Zaba, Lisa C., Shemer, Avner, Fuentes-Duculan, Judilyn, Cardinale, Irma, Kikuchi, Toyoko, Ramon, Michal, Bergman, Reuven +2 more·2009·Journal of Allergy and Clinical Immunology

Abstract

Background Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases. An upregulated TH17/IL-23 pathway was demonstrated in psoriasis. Although potential involvement of TH17 T cells in AD was suggested during acute disease, the role of these cells in chronic AD remains unclear.Objective To examine differences in IL-23/TH17 signal between these diseases and establish relative frequencies of T-cell subsets in AD.Methods Skin biopsies and peripheral blood were collected from patients with chronic AD (n = 12) and psoriasis (n = 13). Relative frequencies of CD4+ and CD8+ T-cell subsets within these 2 compartments were examined by intracellular cytokine staining and flow cytometry.Results In peripheral blood, no significant difference was found in percentages of different T-cell subsets between these diseases. In contrast, psoriatic skin had significantly increased frequencies of TH1 and TH17 T cells compared with AD, whereas TH2 T cells were significantly elevated in AD. Distinct IL-22-producing CD4+ and CD8+ T-cell populations were significantly increased in AD skin compared with psoriasis. IL-22+CD8+ T-cell frequency correlated with AD disease severity.Conclusion Our data established that T cells could independently express IL-22 even with low expression levels of IL-17. This argues for a functional specialization of T cells such that "T17" and "T22" T-cells may drive different features of epidermal pathology in inflammatory skin diseases, including induction of antimicrobial peptides for "T17" T cells and epidermal hyperplasia for "T22" T-cells. Given the clinical correlation with disease severity, further characterization of "T22" T cells is warranted, and may have future therapeutic implications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2009.03.041

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Circulating IL-22 correlates with AD severity and appears to be a key driver of the inflammatory reaction.

    “Circulating IL-22 correlates with the severity of AD and appears as a key driver in the inflammatory reaction116,119.”

    From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [116]

    The Results (page unavailable) correlate the frequency of IL-22-producing CD8+ T cells in AD lesions—not circulating IL-22—with disease severity. The Discussion (page unavailable) suggests an IL-22 contribution to skin changes, but does not establish it as a key driver of the inflammatory reaction. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • IL-22 is an important part of the transcriptomic signature in AD.

    “IL-22 is an important part of the transcriptomic signature in AD116,117.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 30 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Nograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E.
Affiliations
  • Rockefeller University (US)
  • Technion – Israel Institute of Technology (IL)
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2009-06
Volume
123
Issue
6
Pages
1244-1252.e2
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2164098277
Cited by
627
References
30
Citations by year
2026: 13 · 2025: 17 · 2024: 21 · 2023: 23 · 2022: 28 · 2021: 39 · 2020: 39 · 2019: 28 · 2018: 25 · 2017: 49 · 2016: 49 · 2015: 51 · 2014: 52 · 2013: 34 · 2012: 47
FWCI
65.54
Type
journal article
Language
en
Open access
Locations
  • Journal of Allergy and Clinical Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of General Medical Sciences (GM 07739, T32GM007739)
  • National Center for Research Resources (UL1RR024143)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
atopic dermatitis, IL-22, IL-17, Th17 cells, Th2 cells, Th1 cells, IL-23, psoriasis, CD4+ T cells, CD8+ T cells, disease severity, epidermal hyperplasia, antimicrobial peptides, skin inflammation
MeSH terms
Interleukin-22, Adult, Chronic Disease, Dermatitis, Atopic, T-Lymphocytes, Helper-Inducer, Humans, Interleukins, Middle Aged, Psoriasis, T-Lymphocyte Subsets, Interleukin-17, Interleukin-23

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review